These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 30128652)

  • 1. Upgraded Methodology for the Development of Early Diagnosis of Parkinson's Disease Based on Searching Blood Markers in Patients and Experimental Models.
    Kim A; Nigmatullina R; Zalyalova Z; Soshnikova N; Krasnov A; Vorobyeva N; Georgieva S; Kudrin V; Narkevich V; Ugrumov M
    Mol Neurobiol; 2019 May; 56(5):3437-3450. PubMed ID: 30128652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversible Pharmacological Induction of Motor Symptoms in MPTP-Treated Mice at the Presymptomatic Stage of Parkinsonism: Potential Use for Early Diagnosis of Parkinson's Disease.
    Khakimova GR; Kozina EA; Kucheryanu VG; Ugrumov MV
    Mol Neurobiol; 2017 Jul; 54(5):3618-3632. PubMed ID: 27194433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Pilot Study of Changes in the Level of Catecholamines and the Activity of α-2-Macroglobulin in the Tear Fluid of Patients with Parkinson's Disease and Parkinsonian Mice.
    Bogdanov V; Kim A; Nodel M; Pavlenko T; Pavlova E; Blokhin V; Chesnokova N; Ugrumov M
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33947010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in plasma catecholamines levels as preclinical biomarkers in experimental models of Parkinson's disease.
    Kim AR; Ugryumov MV
    Dokl Biochem Biophys; 2015; 464():308-11. PubMed ID: 26518555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MPTP Mouse Model of Preclinical and Clinical Parkinson's Disease as an Instrument for Translational Medicine.
    Mingazov ER; Khakimova GR; Kozina EA; Medvedev AE; Buneeva OA; Bazyan AS; Ugrumov MV
    Mol Neurobiol; 2018 Apr; 55(4):2991-3006. PubMed ID: 28456940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1-Methyl-4-phenyl-1,2,3,6 tetrahydropyridine/probenecid impairs intestinal motility and olfaction in the early stages of Parkinson's disease in mice.
    Choi JG; Huh E; Ju IG; Kim N; Yun J; Oh MS
    J Neurol Sci; 2018 Sep; 392():77-82. PubMed ID: 30031172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of early diagnosis of Parkinson's disease and comprehensive economic analysis of the effect of its implementation].
    Gusev EI; Blokhin VE; Vartanov SA; Martynov MY; Katunina EA; Alesenko AV; Denisova IA; Pavlova EN; Polterovich VM; Kucheryanu VG; Shupik MA; Nodel MR; Kalinkin AL; Sokolov SA; Chubarova TV; Shakleina MV; Pronina TS; Ugryumov MV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(1):9-20. PubMed ID: 33580755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of early diagnosis of Parkinson's disease on animal models based on the intranasal administration of α-methyl-p-tyrosine methyl ester in a gel system.
    Kim A; Pavlova E; Kolacheva A; Bogdanov V; Dilmukhametova L; Blokhin V; Valuev L; Valuev I; Gorshkova M; Ugrumov M
    Biomed Pharmacother; 2022 Jun; 150():112944. PubMed ID: 35405394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of early diagnosis of Parkinson's disease: Illusion or reality?
    Ugrumov M
    CNS Neurosci Ther; 2020 Oct; 26(10):997-1009. PubMed ID: 32597012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-variance RNAs identify Parkinson's disease molecular signature in blood.
    Chikina MD; Gerald CP; Li X; Ge Y; Pincas H; Nair VD; Wong AK; Krishnan A; Troyanskaya OG; Raymond D; Saunders-Pullman R; Bressman SB; Yue Z; Sealfon SC
    Mov Disord; 2015 May; 30(6):813-21. PubMed ID: 25786808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
    Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
    J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Posturo-locomotor markers of preclinical Parkinson's disease.
    Chastan N; Decker LM
    Neurophysiol Clin; 2019 Apr; 49(2):173-180. PubMed ID: 30686671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct Nrf2 Signaling Mechanisms of Fumaric Acid Esters and Their Role in Neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Experimental Parkinson's-Like Disease.
    Ahuja M; Ammal Kaidery N; Yang L; Calingasan N; Smirnova N; Gaisin A; Gaisina IN; Gazaryan I; Hushpulian DM; Kaddour-Djebbar I; Bollag WB; Morgan JC; Ratan RR; Starkov AA; Beal MF; Thomas B
    J Neurosci; 2016 Jun; 36(23):6332-51. PubMed ID: 27277809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Development of early diagnosis of Parkinson's disease based on the search for biomarkers such as premotor symptoms and changes in blood].
    Gusev EI; Katunina EA; Martinov MY; Blokhin VE; Kalinkin AL; Alesenko AV; Nodel MR; Malykhina EA; Titova NV; Katunin DA; Shupik MA; Gutner UA; Maloshitskaya OA; Sokolov SA; Kucheryanu VG; Pavlova EN; Ugrumov MV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(12):7-17. PubMed ID: 33459535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Searching for Biomarkers in the Blood of Patients at Risk of Developing Parkinson's Disease at the Prodromal Stage.
    Katunina EA; Blokhin V; Nodel MR; Pavlova EN; Kalinkin AL; Kucheryanu VG; Alekperova L; Selikhova MV; Martynov MY; Ugrumov MV
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential utility of autoantibodies as blood-based biomarkers for early detection and diagnosis of Parkinson's disease.
    DeMarshall CA; Han M; Nagele EP; Sarkar A; Acharya NK; Godsey G; Goldwaser EL; Kosciuk M; Thayasivam U; Belinka B; Nagele RG;
    Immunol Lett; 2015 Nov; 168(1):80-8. PubMed ID: 26386375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG.
    Takatsu H; Nishida H; Matsuo H; Watanabe S; Nagashima K; Wada H; Noda T; Nishigaki K; Fujiwara H
    J Nucl Med; 2000 Jan; 41(1):71-7. PubMed ID: 10647607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
    Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gynostemma pentaphyllum Ethanolic Extract Protects Against Memory Deficits in an MPTP-Lesioned Mouse Model of Parkinson's Disease Treated with L-DOPA.
    Kim KS; Zhao TT; Shin KS; Park HJ; Cho YJ; Lee KE; Kim SH; Lee MK
    J Med Food; 2017 Jan; 20(1):11-18. PubMed ID: 28005447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages?
    Hopes L; Grolez G; Moreau C; Lopes R; Ryckewaert G; Carrière N; Auger F; Laloux C; Petrault M; Devedjian JC; Bordet R; Defebvre L; Jissendi P; Delmaire C; Devos D
    PLoS One; 2016; 11(4):e0147947. PubMed ID: 27035571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.